3.08 USD
+0.13 (+4.41%)
3.09 USD
+0.01 (+0.32%)
Taking everything into account, ESPR scores 2 out of 10 in our fundamental rating. ESPR was compared to 192 industry peers in the Pharmaceuticals industry. ESPR has a bad profitability rating. Also its financial health evaluation is rather negative. ESPR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ESPR had negative earnings in the past year.
In the past year ESPR has reported a negative cash flow from operations.
ESPR had negative earnings in each of the past 5 years.
In the past 5 years ESPR always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -29.07%, ESPR is in line with its industry, outperforming 52.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.07% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ESPR has a Gross Margin of 58.20%. This is in the better half of the industry: ESPR outperforms 67.19% of its industry peers.
In the last couple of years the Gross Margin of ESPR has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ESPR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 58.2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ESPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ESPR has more shares outstanding
Compared to 5 years ago, ESPR has more shares outstanding
ESPR has a better debt/assets ratio than last year.
2.2 Solvency
ESPR has an Altman-Z score of -5.38. This is a bad value and indicates that ESPR is not financially healthy and even has some risk of bankruptcy.
ESPR's Altman-Z score of -5.38 is on the low side compared to the rest of the industry. ESPR is outperformed by 61.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.38 |
ROIC/WACCN/A
WACC8.58%
2.3 Liquidity
ESPR has a Current Ratio of 1.00. This is a normal value and indicates that ESPR is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ESPR (1.00) is worse than 82.29% of its industry peers.
A Quick Ratio of 0.70 indicates that ESPR may have some problems paying its short term obligations.
With a Quick ratio value of 0.70, ESPR is not doing good in the industry: 86.98% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
ESPR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.87%, which is quite impressive.
Looking at the last year, ESPR shows a small growth in Revenue. The Revenue has grown by 2.83% in the last year.
The Revenue has been growing by 17.50% on average over the past years. This is quite good.
EPS 1Y (TTM)21.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
Revenue 1Y (TTM)2.83%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%69.1%
3.2 Future
ESPR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 67.38% yearly.
The Revenue is expected to grow by 29.10% on average over the next years. This is a very strong growth
EPS Next Y97.14%
EPS Next 2Y36.19%
EPS Next 3Y33.27%
EPS Next 5Y67.38%
Revenue Next Year19.21%
Revenue Next 2Y2.36%
Revenue Next 3Y7.89%
Revenue Next 5Y29.1%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ESPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ESPR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ESPR's earnings are expected to grow with 33.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.19%
EPS Next 3Y33.27%
5. Dividend
5.1 Amount
No dividends for ESPR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.08
+0.13 (+4.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners50.61%
Inst Owner Change-6.33%
Ins Owners0.4%
Ins Owner Change0.35%
Market Cap715.02M
Revenue(TTM)303.80M
Net Income(TTM)-105.83M
Analysts77.14
Price Target6.22 (101.95%)
Short Float %11.22%
Short Ratio3.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.6%
Min EPS beat(2)-183.71%
Max EPS beat(2)86.52%
EPS beat(4)2
Avg EPS beat(4)-25.67%
Min EPS beat(4)-183.71%
Max EPS beat(4)86.52%
EPS beat(8)4
Avg EPS beat(8)56.17%
EPS beat(12)7
Avg EPS beat(12)40.36%
EPS beat(16)10
Avg EPS beat(16)32.71%
Revenue beat(2)2
Avg Revenue beat(2)19.06%
Min Revenue beat(2)10.02%
Max Revenue beat(2)28.11%
Revenue beat(4)4
Avg Revenue beat(4)16.35%
Min Revenue beat(4)10.02%
Max Revenue beat(4)28.11%
Revenue beat(8)7
Avg Revenue beat(8)23.5%
Revenue beat(12)10
Avg Revenue beat(12)16.66%
Revenue beat(16)12
Avg Revenue beat(16)13.5%
PT rev (1m)0.28%
PT rev (3m)5.22%
EPS NQ rev (1m)-4.32%
EPS NQ rev (3m)22.73%
EPS NY rev (1m)0%
EPS NY rev (3m)95.05%
Revenue NQ rev (1m)9.43%
Revenue NQ rev (3m)15.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.35 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.5
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS1.31
BVpS-1.94
TBVpS-1.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.07% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 58.2% | ||
| FCFM | N/A |
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
F-Score2
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | -5.38 |
F-Score2
WACC8.58%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
EPS Next Y97.14%
EPS Next 2Y36.19%
EPS Next 3Y33.27%
EPS Next 5Y67.38%
Revenue 1Y (TTM)2.83%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%69.1%
Revenue Next Year19.21%
Revenue Next 2Y2.36%
Revenue Next 3Y7.89%
Revenue Next 5Y29.1%
EBIT growth 1Y-278.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-228.45%
EBIT Next 3Y5.65%
EBIT Next 5Y45.72%
FCF growth 1Y33.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.79%
OCF growth 3YN/A
OCF growth 5YN/A
ESPERION THERAPEUTICS INC / ESPR FAQ
What is the ChartMill fundamental rating of ESPERION THERAPEUTICS INC (ESPR) stock?
ChartMill assigns a fundamental rating of 2 / 10 to ESPR.
What is the valuation status of ESPERION THERAPEUTICS INC (ESPR) stock?
ChartMill assigns a valuation rating of 1 / 10 to ESPERION THERAPEUTICS INC (ESPR). This can be considered as Overvalued.
What is the profitability of ESPR stock?
ESPERION THERAPEUTICS INC (ESPR) has a profitability rating of 1 / 10.
How financially healthy is ESPERION THERAPEUTICS INC?
The financial health rating of ESPERION THERAPEUTICS INC (ESPR) is 1 / 10.
Can you provide the expected EPS growth for ESPR stock?
The Earnings per Share (EPS) of ESPERION THERAPEUTICS INC (ESPR) is expected to grow by 97.14% in the next year.